TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2422-2429

  Jelinek, Ivett ^a   Leonard, Joshua N ^a,c   Price, Graeme E ^b   Brown, Kevin N ^a   Meyer Manlapat, Anna ^a,d   Goldsmith, Paul K ^a   Wang, Yan ^a   Venzon, David ^a   Epstein, Suzanne L ^b   Segal, David M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c Northwestern University   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD86 ANTIGEN; DOUBLE STRANDED RNA; INTERLEUKIN 12P40; INTERLEUKIN 6; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOSOME; ENZYME ACTIVATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELLS, CULTURED; CPG ISLANDS; CROSS-PRIMING; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; RNA, DOUBLE-STRANDED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 3;

EID: 79951828168     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002845     Document Type: Article

References (64)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
2. Steinman, R. M. 2007. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 37(Suppl. 1): S53-S60.
3. Batista, F. D., and N. E. Harwood. 2009. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9: 15-27.
4. Guermonprez, P., J. Valladeau, L. Zitvogel, C. Théry, and S. Amigorena. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20: 621-667.
5. Kapsenberg, M. L. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3: 984-993.
6. Segura, E., and J. A. Villadangos. 2009. Antigen presentation by dendritic cells in vivo. Curr. Opin. Immunol. 21: 105-110.
7. Vyas, J. M., A. G. Van der Veen, and H. L. Ploegh. 2008. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8: 607-618.
8. Steinman, R. M. 2003. The control of immunity and tolerance by dendritic cell. Pathol. Biol. (Paris) 51: 59-60.
9. Steinman, R. M., D. Hawiger, K. Liu, L. Bonifaz, D. Bonnyay, K. Mahnke, T. Iyoda, J. Ravetch, M. Dhodapkar, K. Inaba, and M. Nussenzweig. 2003. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. N. Y. Acad. Sci. 987: 15-25.
10. Granucci, F., I. Zanoni, and P. Ricciardi-Castagnoli. 2008. Central role of dendritic cells in the regulation and deregulation of immune responses. Cell. Mol. Life Sci. 65: 1683-1697.
11. Lutz, M. B., and C. Kurts. 2009. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur. J. Immunol. 39: 2325-2330.
12. Hemmi, H., and S. Akira. 2005. TLR signalling and the function of dendritic cells. Chem. Immunol. Allergy 86: 120-135.
13. Benko, S., Z. Magyarics, A. Szabó, and E. Rajnavölgyi. 2008. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol. Chem. 389: 469-485.
14. Iwasaki, A., and R. Medzhitov. 2010. Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
15. Reis e Sousa, C. 2004. Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16: 21-25.
16. Kawai, T., and S. Akira. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 1143: 1-20.
17. Kumar, H., T. Kawai, and S. Akira. 2009. Pathogen recognition in the innate immune response. Biochem. J. 420: 1-16.
18. Naik, S. H. 2008. Demystifying the development of dendritic cell subtypes, a little. Immunol. Cell Biol. 86: 439-452.
19. Kwissa, M., S. P. Kasturi, and B. Pulendran. 2007. The science of adjuvants. Expert Rev. Vaccines 6: 673-684. (Pubitemid 47607845)
20. Wilson-Welder, J. H., M. P. Torres, M. J. Kipper, S. K. Mallapragada, M. J. Wannemuehler, and B. Narasimhan. 2009. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98: 1278-1316.
21. Pichlmair, A., and C. Reis e Sousa. 2007. Innate recognition of viruses. Immunity 27: 370-383.
22. Takeuchi, O., and S. Akira. 2009. Innate immunity to virus infection. Immunol. Rev. 227: 75-86.
23. Botos, I., L. Liu, Y. Wang, D. M. Segal, and D. R. Davies. 2009. The toll-like receptor 3:dsRNA signaling complex. Biochim. Biophys. Acta 1789: 667-674.
24. Vercammen, E., J. Staal, and R. Beyaert. 2008. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin. Microbiol. Rev. 21: 13-25.
25. Matsumoto, M., and T. Seya. 2008. TLR3: interferon induction by doublestranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60: 805-812.
26. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
27. Leonard, J. N., R. Ghirlando, J. Askins, J. K. Bell, D. H. Margulies, D. R. Davies, and D. M. Segal. 2008. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc. Natl. Acad. Sci. USA 105: 258-263.
28. Liu, L., I. Botos, Y. Wang, J. N. Leonard, J. Shiloach, D. M. Segal, and D. R. Davies. 2008. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320: 379-381.
29. Diebold, S. S., O. Schulz, L. Alexopoulou, W. W. Leitner, R. A. Flavell, and C. Reis e Sousa. 2009. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther. 16: 359-366.
30. Schulz, O., S. S. Diebold, M. Chen, T. I. Näslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljeström, and C. Reis e Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
31. Homan, E. R., R. P. Zendzian, L. D. Schott, H. B. Levy, and R. H. Adamson. 1972. Studies on poly I:C toxicity in experimental animals. Toxicol. Appl. Pharmacol. 23: 579-588.
32. Robinson, R. A., V. T. DeVita, H. B. Levy, S. Baron, S. P. Hubbard, and A. S. Levine. 1976. A phase I-II trial of multiple-dose polyriboinosic- polyribocytidylic acid in patieonts with leukemia or solid tumors. J. Natl. Cancer Inst. 57: 599-602.
33. Naik, S. H., A. I. Proietto, N. S. Wilson, A. Dakic, P. Schnorrer, M. Fuchsberger, M. H. Lahoud, M. O'Keeffe, Q. X. Shao, W. F. Chen, et al. 2005. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J. Immunol. 174: 6592-6597. (Pubitemid 40705619)
34. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176: 1693-1702.
35. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
36. Ingulli, E. 2007. Tracing tolerance and immunity in vivo by CFSE-labeling of administered cells. Methods Mol. Biol. 380: 365-376.
37. Edwards, A. D., S. S. Diebold, E. M. Slack, H. Tomizawa, H. Hemmi, T. Kaisho, S. Akira, and C. Reis e Sousa. 2003. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33: 827-833.
38. Heath, W. R., and F. R. Carbone. 2009. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat. Immunol. 10: 1237-1244.
39. Steinman, R. M., and J. Idoyaga. 2010. Features of the dendritic cell lineage. Immunol. Rev. 234: 5-17.
40. Liu, K., and M. C. Nussenzweig. 2010. Origin and development of dendritic cells. Immunol. Rev. 234: 45-54.
41. Xu, Y., Y. Zhan, A. M. Lew, S. H. Naik, and M. H. Kershaw. 2007. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J. Immunol. 179: 7577-7584.
42. Belz, G. T., C. M. Smith, D. Eichner, K. Shortman, G. Karupiah, F. R. Carbone, and W. R. Heath. 2004. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172: 1996-2000.
43. den Haan, J. M., S. M. Lehar, and M. J. Bevan. 2000. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192: 1685-1696.
44. Bedoui, S., P. G. Whitney, J. Waithman, L. Eidsmo, L. Wakim, I. Caminschi, R. S. Allan, M. Wojtasiak, K. Shortman, F. R. Carbone, et al. 2009. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10: 488-495.
45. Shortman, K., and W. R. Heath. 2010. The CD8+ dendritic cell subset. Immunol. Rev. 234: 18-31.
46. Kato, H., O. Takeuchi, E. Mikamo-Satoh, R. Hirai, T. Kawai, K. Matsushita, A. Hiiragi, T. S. Dermody, T. Fujita, and S. Akira. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205: 1601-1610.
47. Pichlmair, A., O. Schulz, C. P. Tan, J. Rehwinkel, H. Kato, O. Takeuchi, S. Akira, M. Way, G. Schiavo, and C. Reis e Sousa. 2009. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 83: 10761-10769.
48. Epstein, S. L. 2003. Control of influenza virus infection by immunity to conserved viral features. Expert Rev. Anti. Infect. Ther. 1: 627-638.
49. Hildner, K., B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, et al. 2008. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322: 1097-1100.
50. Edelson, B. T., W. KC, R. Juang, M. Kohyama, L. A. Benoit, P. A. Klekotka, C. Moon, J. C. Albring, W. Ise, D. G. Michael, et al. 2010. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J. Exp. Med. 207: 823-836.
51. Jongbloed, S. L., A. J. Kassianos, K. J. McDonald, G. J. Clark, X. Ju, C. E. Angel, C. J. Chen, P. R. Dunbar, R. B. Wadley, V. Jeet, et al. 2010. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207: 1247-1260.
52. Crozat, K., R. Guiton, V. Contreras, V. Feuillet, C. A. Dutertre, E. Ventre, T. P. Vu Manh, T. Baranek, A. K. Storset, J. Marvel, et al. 2010. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 207: 1283-1292.
53. Poulin, L. F., M. Salio, E. Griessinger, F. Anjos-Afonso, L. Craciun, J. L. Chen, A. M. Keller, O. Joffre, S. Zelenay, E. Nye, et al. 2010. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 207: 1261-1271.
54. Bachem, A., S. Güttler, E. Hartung, F. Ebstein, M. Schaefer, A. Tannert, A. Salama, K. Movassaghi, C. Opitz, H. W. Mages, et al. 2010. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207: 1273-1281.
55. Yoneyama, M., and T. Fujita. 2010. Recognition of viral nucleic acids in innate immunity. Rev. Med. Virol. 20: 4-22.
56. Takeuchi, O., and S. Akira. 2008. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 20: 17-22.
57. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
58. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529. (Pubitemid 38314424)
59. Jasani, B., H. Navabi, and M. Adams. 2009. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27: 3401-3404.
60. Poast, J., H. M. Seidel, M. D. Hendricks, J. A. Haslam, H. B. Levy, and S. Baron. 2002. Poly I:CLC induction of the interferon system in mice: an initial study of four detection methods. J. Interferon Cytokine Res. 22: 1035-1040. (Pubitemid 35379015)
61. Lau, Y. F., L. H. Tang, A. W. McCall, E. E. Ooi, and K. Subbarao. 2010. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J. Virol. 84: 8639-8649.
62. McCluskie, M. J., and A. M. Krieg. 2006. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr. Top. Microbiol. Immunol. 311: 155-178.
63. Epstein, S. L., W. P. Kong, J. A. Misplon, C. Y. Lo, T. M. Tumpey, L. Xu, and G. J. Nabel. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
64. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749. (Pubitemid 23114660)